GleamWall
中文EN

ELOX Eloxx Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1035354 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.6%
ROA-27.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets29.5%
Debt / equity0.00x
Current ratio3.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.17x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$6.36M
R&D expense$3.06M$3.58M
SG&A expense$3.38M$5.25M
Operating income-$6.44M-$2.47M
Pretax income-$6.00M-$3.14M
Income tax$0$0
Net income-$6.00M-$3.14M
EBITDA-$6.44M-$2.43M
EPS (basic)-0.49-0.84
EPS (diluted)-0.49-0.84
Weighted avg. shares (diluted)12.35M3.76M
Balance sheet
Cash & equivalents$4.79M$111,000
Current assets$5.27M$2.98M
PP&E, net$0$0
Total assets$5.27M$2.98M
Current liabilities$17.18M$27.31M
Short-term debt$1.00M$6.52M
Long-term debt$0$0
Total debt$1.00M$6.52M
Total liabilities$17.18M$27.31M
Shareholders' equity-$11.91M-$24.34M
Net debt-$3.79M$6.41M
Shares outstanding435,4323.53M
Cash flow statement
Operating cash flow-$6.33M-$4.71M
Investing cash flow$1,000$38,000
Financing cash flow$11.00M$3.44M
Depreciation & amortization$0$35,000
Stock-based compensation$235,000$541,000

Free plan shows the latest 2 periods; Pro shows all 30 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.